Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
serotonin/oksendamine
Link salvestatakse lõikelauale
Leht 1 alates 39 tulemused
Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This invention relates to a method of alleviating both motion sickness and emesis induced by chemical agents, and more particularly to the use of compositions which stimulate serotonin-1A receptors in mammals to achieve this purpose.
There are currently no known strategies or agents which are
Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
1. INTRODUCTION
The present invention relates to a novel method of controlling nausea and vomiting (or emesis) in mammals utilizing certain substituted-phenylalkylamino (and aminoacid) derivatives which do not exhibit certain side effects of the type attributable to dopamine blocking compounds which
Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS-REFERENCE TO RELATED APPLICATION
This application claims, under 35 U.S.C. .sctn.119(a), the benefit of Korean Patent Application No. 10-2007-0084322 filed Aug. 22, 2007, the entire contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The
Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine is a neurotransmitter found in various parts of the central nervous system. It is most prevalent in the substantia nigra (A9), the neostriatum, and the ventral tegmental area (A10). Dopamine binds to two general classes of receptors, termed D1- and D2-like
Methods for treating emesis and nausea using optically pure R(+) ondansetron
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and
4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application claims the benefit of Provisional Application 60/069,890 Jan. 5, 1996.
The present invention is directed to certain novel compounds and their use as pharmaceutical agents having unique central nervous system activity.
This invention relates to 4,5-dihydronaphth[1,2-c]isoxazoles and
Naphthothiopyranone derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
DESCRIPTION
1. Technical Field
The present invention relates to naphthothiopyranone derivatives, and more particularly relates to naphthothiopyranone derivatives having the antagonist effect of 5-HT (serotonin) at 5-HT.sub.3 (serotonin 3) receptors.
Background Art
Compounds described in EP-A-364274
2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivatives, and production method and use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This application is a 371 of PCT/JP93/01589 filed Nov. 4, 1993.
1. Technical Field
The present invention relates to novel 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivatives, a production method thereof, and a pharmaceutical use thereof. The 2-alkoxy-5,6,7,8-tetrahydroquinoxaline derivatives are
Deuterium-enriched pyridinonecarboxamides and derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SUMMARY OF THE INVENTION
The present invention is concerned with deuterium-enriched pyridinone carboxamides and derivatives thereof of formula I,
##STR00002##
Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),
Deuterium-enriched pyridinonecarboxamides and derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SUMMARY OF THE INVENTION
The present invention is concerned with deuterium-enriched pyridinonecarboxamides and derivatives thereof of formula 1,
##STR00002## Wherein, R.sub.1 and R.sub.2 are independently, H, D (deuterium with enrichment of 1%-100%), F, Cl, CD.sub.3 (methyl-d.sub.3),
Ligands for monoamine receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in
Ligands for monoamine receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in
Ligands for monoamine receptors and transporters, and methods of use thereof
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Dopamine, norepinephrine and serotonin are mammalian monoamine neurotransmitters that play important roles in a wide variety of physiological processes. Therefore, compounds that selectively modulate the activity of these three neurotransmitters, either individually, in
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
